/
Oncology
Endometrial Cancer
126
Pipeline Programs↗
159
Active Trials↗
71
Companies Involved↗
Endometrial Cancer is a highly competitive landscape with 126 programs across 71 companies. The most active players are AstraZeneca, Roche, Incyte. 28 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 111
Phase 273
Phase 328
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
86 of 114 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 114 classified programs, each share of the total. Modality classified for 94% of 126 pipeline programs.
Analysis
Trial Status
393
clinical trials
Completed146 · 37%
Recruiting79 · 20%
Active, not recruiting46 · 12%
Unknown status40 · 10%
Not yet recruiting33 · 8%
Terminated30 · 8%
Other19 · 5%
Clinical Trials
Trial Activity
393 trials
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
Recruiting·—·Preclinical·NCT07116213·20 enrolled
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Obese Progestin-insensitive Early-stage Endometrial Cancer Patients With Conservative Treatment
Recruiting·—·Preclinical·NCT06379113·29 enrolled
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Non-obese Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment
Recruiting·—·Preclinical·NCT05316935·80 enrolled
Page 1 of 27
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)